Khanna Vidhi, Panyam Jayanth, Griffith Thomas S
Department of Pharmaceutics, University of Minnesota, Minneapolis, MN 55455, USA.
Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.
Immunotherapy. 2020 Mar;12(4):255-267. doi: 10.2217/imt-2019-0118. Epub 2020 Mar 24.
Over the last decade, antibodies have become an important component in the arsenal of cancer therapeutics. High-specificity, low off-target effects, desirable pharmacokinetics and high success rate are a few of the many attributes that make antibodies amenable for development as drugs. To design antibodies for successful clinical applications, however, it is critical to have an understanding of their structure, functions, mechanisms of action and pharmacokinetic/pharmacodynamic properties. This review highlights some of these key aspects, as well as certain limitations encountered, with monoclonal antibody therapy. Further, we discuss rational combination therapies for clinical applications, some of which could help overcome the limitations.
在过去十年中，抗体已成为癌症治疗手段中的重要组成部分。高特异性、低脱靶效应、理想的药代动力学和高成功率是使抗体适合开发成药物的众多特性中的几个。然而，要设计出能成功用于临床的抗体，了解其结构、功能、作用机制以及药代动力学/药效学特性至关重要。本综述重点介绍了单克隆抗体治疗的一些关键方面以及遇到的某些局限性。此外，我们还讨论了临床应用中的合理联合疗法，其中一些可能有助于克服这些局限性。
